Captor Therapeutics

Inspired
by nature

We are reprogramming protein
fate to treat the untreatable.

who are we?

About us

Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”.

Captor Therapeuticsis a Swiss-Polish company with offices in Basel, Switzerland and operations in state-of-the-art laboratories in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.

meet us

what are we doing?

Story

Since millions of years ago fitohormones (e.g. auxins) have been reprograming TIR1 E3 ubiquitin ligase to change its ubiquitylation and degradation specificity.

1999

Kenten J. and Roberts S. filed a patent application for compounds activating ubiquitination of a target protein. An idea of Ubiquitin Proteasome System modulation emerged.
2001

Proof of Principle - targeted protein degradation with peptidic bifunctional moleculewas reported (Sakamoto K. et al., PNAS).
2004

Nobel Prize in Chemistry was awarded for the discovery of ubiquitin-mediated protein degradation (Aaron Ciechanover, Avram Hershko and Irwin Rose).
2008

First small molecule bifunctional degrader was reported (Smith A. et al., Bioorg. Med. Chem. Lett.).
2010

Cereblon E3 ubiquitin ligase complex was identified as thalidomide’s target. The discovery fuelled progress in a Targeted Protein Degradation technology (Ito T. et al., Science).
2017

Obterons™ at Captor Therapeutics – direct degraders inspired by nature.

what's next?

what are we doing?

Our approach

Thanks to our expertise in targeted protein degradation we take a multi-faceted approach to eliminate pathological proteins. Our technology consists of bifunctional molecules and direct degraders.

Our proprietary Obteron™ platform enables the robust discovery of therapeutic compounds with good biopharmaceutical properties. These compounds lead to efficient protein degradation via proteasome and/or autophagosome.

Supported by over 44 mln EUR from European grants and private investors, we are currently working on several projects aiming at (1) advancement of a protein degradation platform and (2) development of first-in-class therapeutics for autoimmune and oncological indications.